首页|Old drug, new Trick? The rationale for the treatment of COVID-19 with activated protein C
Old drug, new Trick? The rationale for the treatment of COVID-19 with activated protein C
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Elsevier
As the COVID-19 pandemic continues， researchers seek to identify efficacious treatments。 Current approaches to COVID-19 therapeutics focus on antiviral agents， convalescent plasma， monoclonal antibodies， immunomodulators and more traditional therapies such as steroids [1-6]。 Reversing disturbances in coagulation has also been identified as a priority area for candidate therapies， such as through the Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 adaptive clinical trial (ACTIV-4) which is currently evaluating aspirin， heparins and apixaban [7]。 Since there is a clear relationship between mechanisms of coagulation and the immune response， it is possible that reversing disturbances in coagulation may diminish the dysregulated immune response observed in COVID-19。 The basis for this hypothesis is described below and is followed by discussion of a proposed candidate therapy - activated protein C。 By treating COVID-19 patients using a novel approach， which does not focus on immune-based or antiviral treatments， but instead which addresses both the anti-thrombotic and inflammatory consequences of infection， the hope is that new therapeutic targets can be considered and new candidate therapies， such as activated protein C， may be evaluated。
COVID-19Activated protein CCOVID-19 therapeutics
Pestka, Steven B.
展开 >
Tufts Univ, Newton Wellesley Hosp, Sch Med, Dept Med, 2014 Washington St, Newton, MA 02462 USA
NSTL
Elsevier
